Shareholders provide further support for Rett syndrome
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Later from Neuren Pharmaceuticals
- Trofinetide successful in Phase 2 trial in Fragile X
- Appendix 4E and Financial Report 31 December 2015
- Neuren 2011 Preliminary Final Report
- Neuren Completes Phase II trial Cohort 2
- Neuren to proceed with oral NNZ2566 trial
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals